Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Jersey for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Jersey only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Jersey (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ahmed Abdel-megid (NPI 1134313745)

Field	Value
Entity Type	Individual
Organization	Ahmed Abdel-megid
Address	56 Union Ave
City	Somerville
State	NJ
ZIP	08876
Taxonomy	Internal Medicine Physician
NPI Enumerated	August 28, 2007

Payer Source	Total Paid
Medicare	$2.6M
Medicaid	$0

Key Findings

This provider’s billing is effectively single-payer: total Medicare revenue is $2.6M while there is no Medicaid billing on file, so the practice’s revenue and utilization profile should be evaluated primarily through a Medicare lens and Medicaid network or population exposure appears minimal. The absence of Medicaid billing may limit the provider’s access to dual-eligible populations and reduces Medicaid-driven leverage in payer negotiations.

Revenue is highly concentrated in a small set of biologic drug codes: the precomputed top 3 Medicare codes by revenue account for 59.6% of this provider's total Medicare revenue, led by J0129 $626.5K (24.5%), J0717 $566.4K (22.2%), and J1602 $329.3K (12.9%). This concentration implies that shifts in utilization or reimbursement for these three agents would materially affect overall Medicare receipts.

The code mix indicates an infusion- and injection-focused operation: the largest revenue drivers are biologic injections (J0129, J0717, J1602) and there is substantial activity in other injected biologics and bone agents such as J0897 $310K (12.1%) and J3111 $141.1K (5.5%). In addition, the presence of chemotherapy administration codes 96401 $86.7K (3.4%) and 96413 $77.8K (3.0%) suggests on-site administration of antineoplastic agents and monitoring services rather than a pure office-primary-care panel.

Competitive standing for the top biologics is above typical national volume: J0129 ranks #161 of 1221 providers (87th percentile; typical, unremarkable volume), J0717 ranks #72 of 848 providers (91th percentile; typical, unremarkable volume), and J1602 ranks #128 of 1041 providers (88th percentile; typical, unremarkable volume), indicating a meaningful national-level presence for these specific drugs even if the vendor descriptions label the volumes as typical. These percentiles suggest the provider is a solid national participant for specific biologic administrations rather than a marginal biller.

Several codes are statistical outliers or notably above typical volumes, flagging distinct service strengths: 99214 has 1.9K claims and $197.3K revenue (7.7%) and ranks #1670 of 479517 providers (100th percentile; extreme outlier), while 96401 ranks #25 of 3868 providers (99th percentile; extreme outlier) and 96413 ranks in the 96th percentile (notably above typical national volume). The combination of very high-use E/M code 99214 and top-tier chemotherapy administration ranks implies heavy throughput of complex visits and infusion sessions.

There is also notable revenue from bone-targeted injectable therapies that broaden the service mix: J0897 (denosumab) contributes $310K (12.1%) and ranks #399 of 10057 providers (96th percentile; notably above typical national volume), and J3111 (romosozumab) contributes $141.1K (5.5%). This suggests the practice captures referrals or treats patients for osteoporosis and bone-related indications in addition to autoimmune and oncology-supportive care.

Tenure is long-standing: NPI enumerated 2007-08-28 (~19 years ago), indicating an established billing history and likely stable operational footprint. Given the provider’s longevity and the concentration of revenue in a handful of biologic and infusion codes, business risk is concentrated in these service lines — changes in prescribing patterns, site-of-care migration, or reimbursement policy for these agents would disproportionately affect revenue.

Operational and contracting implications: the provider’s Medicare-centered mix, infusion-heavy service line, and extreme outlier ranks for selected E/M and chemotherapy administration codes suggest this entity is best evaluated as an infusion-capable internal medicine practice when sizing networks or forecasting utilization. The lack of Medicaid billing means payers should not assume Medicaid-level volumes when assessing network capacity or negotiating managed-Medicare arrangements.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

29 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	18,430	$30	$626.5K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	141,600	$1	$566.4K
J1602	Injection, golimumab, 1 mg, for intravenous use	32,930	$10	$329.3K
J0897	Injection, denosumab, 1 mg	17,220	$20	$310K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,880	$110	$197.3K
J3111	Injection, romosozumab-aqqg, 1 mg	17,640	$10	$141.1K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	1,330	$70	$86.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	670	$120	$77.8K
20611	In this procedure, the provider inserts a needle through the skin of a patient and into a major joint or bursa, typically the shoulder, hip, knee, or subacromial bursa, and then uses the syringe…	510	$90	$45.8K
J7322	Hyaluronan or derivative, hymovis or hymovis one, for intra-articular injection, 1 mg	2,910	$10	$37.8K

Showing 1–10 of 29

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 29 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Jersey Distribution

Ahmed Abdel-megid — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Jersey

Full comparison — all codes billed, vs. state median

29 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	5	40	7,600	$30	$297K
J0717	4	60	42,300	$1	$219.5K
J1602	5	40	12,580	$10	$165.7K
J3111	8	30	12,600	$10	$107.3K
J0897	13	380	3,060	$20	$87.8K
J7320	29	40	3,050	$10	$41K
J7329	32	70	2,680	$10	$35.7K
96413	13	230	190	$110	$26.6K
J7322	11	50	1,520	$10	$26.1K
99214	49	13,640	130	$90	$23.6K

Showing 1–10 of 29

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ahmed Abdel-megid, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ghousia Alikhan	MA	Rheumatology Physician	$329.8K	$0

Nearby Providers

Other providers in the same ZIP code as Ahmed Abdel-megid, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Tricounty Care Management Organization	NJ	Case Management Agency	$0	$49.5M
Midland Adult Services, Inc.	NJ	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$42.6M
Robert Wood Johnson University Hospital Inc	NJ	General Acute Care Hospital	$0	$42.3M
Obi Imegwu	NJ	Vascular Surgery Physician	$1.6M	$0
Able Medical Transportation, Inc.	NJ	Land Ambulance	$828K	$505.4K
Patrick Saulino	NJ	Cardiovascular Disease Physician	$387.5K	$0
Ambulatory Surgical Center Of Somerville LLC	NJ	Ambulatory Surgical Clinic/Center	$308.9K	$0
Neel Shah	NJ	Urology Physician	$261.5K	$0
Nimer Mian	NJ	Neurology Physician	$252.1K	$0
Tsuey-ling Chen	NJ	Anatomic Pathology & Clinical Pathology Physician	$206.8K	$0

Ahmed Abdel-megid — Billing Profile & Reimbursement Data

Sign up for Ahmed Abdel-megid — Billing Profile & Reimbursement Data policy alerts

Ahmed Abdel-megid — Billing Profile & Reimbursement Data

Sign up for Ahmed Abdel-megid — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References